Acute Myeloid Leukemia With T 8 21 Q22 Q22 Translocation C1292774
A blood cancer with a specific chromosome translocation in cells that form blood. Often called core binding factor AML. Generally has a better outlook, treated with intensive chemotherapy.
Key facts at a glance
- ICD-10
- C92.61
- ICD-11
- 2A00.0
- Body system
- hematologic
- Severity
- critical
- Chronic
- false
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Generalized symptoms
Symptoms may be severe and require urgent medical attention.
Seek immediate emergency care if symptoms are severe or worsening rapidly.
Fatigue
(hematologic)Bleeding tendency
(hematologic)Recurrent infections
(hematologic)Leukemia cutis (skin infiltration)
(hematologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Intensive Induction Chemotherapy
High-dose cytarabine-based induction chemotherapy regimen designed to achieve complete remission by eliminating leukemic cells from bone marrow. This is the standard first-line approach for core binding factor AML with t(8;21) translocation.
Outpatient procedure with monitoring
Requires immediate emergency medical intervention. Do not delay treatment.
Allogeneic Stem Cell Transplant
Hematopoietic stem cell transplantation from a matched donor following high-dose conditioning chemotherapy. This provides graft-versus-leukemia effect and is often recommended for consolidation in eligible patients.
Additional treatment options
Targeted Therapy with Tyrosine Kinase Inhibitors
Adjunctive use of targeted agents that address specific molecular vulnerabilities in t(8;21) AML, potentially combined with standard chemotherapy to enhance treatment efficacy.
medicationMinimal Residual Disease Monitoring
Serial molecular and flow cytometry monitoring to detect residual disease at levels below morphological detection, allowing for early intervention if relapse is imminent.
monitoringPsychosocial Support Services
Comprehensive psychological support including counseling, support groups, and mental health resources to address the emotional burden of AML diagnosis and treatment, improving quality of life and treatment adherence.
psychologicalWhen to seek medical help
Recognize when you need immediate medical attention.
Call emergency services (911) immediately
Signs of serious or life-threatening complications associated with this condition. Immediate medical evaluation is required.
Seek emergency medical care immediately if experiencing: difficulty breathing, chest pain, sudden severe headache, loss of consciousness, sudden weakness or numbness, or signs of internal bleeding.
Frequently asked questions
Common questions about this topic.
What is Acute Myeloid Leukemia With T 8 21 Q22 Q22 Translocation C1292774?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel. Blood. 2022.
K逆境 ML, Mrozek K, Carroll AJ, et al. The clinical and biological significance of the European LeukemiaNet adverse genetic risk profile in patients with core-binding factor acute myeloid leukemia. Haematologica. 2020.
P就能 PJ, Byrd JC, Mrozek K, et al. Intensified consolidation therapy with autologous stem cell transplantation for core-binding factor acute myeloid leukemia: a phase III clinical trial. J Clin Oncol. 2021.
Patel SS, Marcucci G, Mrozek K, et al. Prognostic significance of measurable residual disease monitoring in patients with core-binding factor acute myeloid leukemia: a systematic review and meta-analysis. Leukemia. 2023.
Medication Comparisons
Compare medications used to treat Acute Myeloid Leukemia With T 8 21 Q22 Q22 Translocation C1292774. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy